Lumexa's Raise Came From the Tax Line; Its Future Came From a Fee Schedule
Q3 delivered genuine cash-flow momentum and a $44B bigger sandbox — but the EPS upgrade was arithmetic, and the stock fell 31% in four days on the way into the print.
LMRI · Earnings Call · 2026-11-10
The raise that wasn't an operating raise
Lumexa Imaging reported Q3 2026 with consolidated revenue of $272 million, up 5%, adjusted EBITDA of $62.6 million versus $59.1 million a year ago, and a 23.0% adjusted EBITDA margin that ticked up from 22.8% — the first year-over-year margin expansion since the company went public. That last detail matters more than it looks: Tony Martin, the CFO, had spent two prior calls explaining why the first half of 2026 would look flat while the back half carried the year. The 45/55 first-half/second-half split he first laid out in August landed almost exactly. Then came the guidance section, which is where the quarter gets interesting in a way the headline does not.Narrowing a $6 million range to a $4 million range while holding the $238 million midpoint is not a raise; it is housekeeping. Consolidated revenue guidance was reiterated outright at $1.045 billion to $1.097 billion. The one number that moved materially was adjusted EPS — to $0.86 to $0.90 from $0.71 to $0.77, a roughly 20% lift at the midpoint — and Martin was admirably plain about why: “This increase is driven primarily by a lowered assumed effective tax rate for the year. With no change to our underlying operating assumptions.” — J. Anthony Martin, Chief Financial Officer · 2026-11-10 So the quarter's most quotable upgrade is a tax-rate assumption, and management says so out loud. That is not a red flag by itself — it is honest disclosure — but it is the single most important thing to hold onto when the stock's reaction is being read. The business did improve; the guidance barely did.We are again narrowing our adjusted EBITDA guidance range. This time, to $236 million to $240 million. Versus the previous range of $235 million to $241 million. While maintaining the midpoint.
From FastScan to fee schedules: the narrative rotated
The company's own keyword record shows an unusually clean rotation. Through the first three quarters of 2026, the top of the Lumexa stack was operational and technological: Lumexa Connect, Virtual MRI, FastScan, PET machines, the Technologist Advancement Academy, referring physicians, strategic service lines. In this quarter's top-30, the technology vocabulary is largely gone and the policy vocabulary has taken its place — hospital outpatient, site neutrality, addressable market, Medicare reimbursement, and conversion factor all enter fresh. FastScan, which spiked into the top-30 as recently as last quarter, is the single largest keyword decliner in the current snapshot. That is not because the technology stopped working — Caitlin Zulla noted it is now deployed across the majority of the enterprise, shortening MRI acquisition by up to 40% — but because it has become plumbing rather than a growth story. What replaced it is the finalization of CMS's 2027 hospital outpatient rule on site-neutrality. Zulla's framing is that this takes Lumexa's addressable market from roughly $33 billion in independent diagnostic testing facilities to about $77 billion, by adding a $44 billion hospital-outpatient imaging pool. That is the biggest new number in the release, and it is worth noting it is a market-sizing number, not a revenue number. The discipline of the language is the tell. This is the same claim the company made in August, when the rule was only proposed:And in November, with the rule finalized, the tone barely moved: “We see the movement towards site-neutral reimbursement as a tailwind that would unfold over years, not quarters.” — Caitlin Zulla, Chief Executive Officer · 2026-11-10 That consistency is credible — management is not pretending a policy change will show up in Q1 2027 revenue. But it also means the near-term case still rests on the same levers as before: De Novos (five opened year-to-date, an 8-to-10 target, three opened in early November across Texas, South Carolina and North Carolina), advanced modality mix at a record 38.2% of system-wide volume, and PET growth of 19.5%. One genuine corroboration: the global tape's top 30-day advancer is the de novo facility cluster — RadNet, Acadia and Surgery Partners — up over 30% in a month. Lumexa's growth architecture is riding a wave the market is already paying for elsewhere in the outpatient complex.I see this as a multiyear catalyst versus something that's going to change our results immediately. What I do think it does is it reinforces the conversations that are already happening.